Tenaya Therapeutics reported a net margin of -3,909.28% for the quarter ended Jun 2026. These financial ratios cover 20 quarters of results from Sep 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||
| EBT Margin | -8,565.33% | -3,909.28% | ||||||||||||||||||
| EBIT Margin | -8,917.78% | -3,971.89% | ||||||||||||||||||
| EBITDA Margin | -8,917.78% | -3,971.89% | ||||||||||||||||||
| Operating Margin | -8,917.78% | -3,971.89% | ||||||||||||||||||
| Net Margin | -8,565.33% | -3,909.28% | ||||||||||||||||||
| FCF Margin | -8,343.56% | -323.33% | ||||||||||||||||||
| Efficiency | ||||||||||||||||||||
| Assets AverageAssets Avg. | 244.34M | 322.99M | 297.84M | 268.71M | 241.12M | 252.63M | 262.14M | 233.05M | 207.08M | 181.96M | 177.71M | 174.04M | 151.88M | 130.26M | 131.95M | 133.05M | 113.57M | 125.95M | 141.00M | 114.31M |
| Asset Utilization RatioAsset Util. | 0.01 | |||||||||||||||||||
| Valuation | ||||||||||||||||||||
| Price to EarningsP/E | -30.41 | -12.85 | -15.67 | -8.20 | -3.91 | -2.69 | -6.00 | -11.97 | -5.96 | -7.40 | -12.74 | -8.31 | -5.96 | -5.19 | -2.33 | -4.28 | -13.30 | -5.39 | -7.80 | -3.82 |
| Price to SalesP/S | 667.78 | 149.49 | ||||||||||||||||||
| Price to BookP/B | 1.83 | 1.21 | 1.95 | 1.04 | 0.61 | 0.37 | 0.88 | 2.10 | 1.05 | 1.59 | 2.60 | 1.83 | 1.36 | 1.33 | 0.52 | 1.00 | 3.26 | 0.88 | 1.41 | 2.39 |
| Enterprise Value | 274.93M | 84.76M | 276.19M | 51.97M | -29.46M | -96.43M | 42.77M | 265.86M | 51.93M | 116.75M | 288.40M | 145.25M | 73.43M | 62.31M | -25.52M | 27.94M | 213.43M | 8.29M | 69.35M | 87.83M |
| EV to EBIT | -15.02 | -3.24 | -8.87 | -1.82 | 0.94 | 2.79 | -1.27 | -7.57 | -1.68 | -3.71 | -8.54 | -4.71 | -2.75 | -2.53 | 0.93 | -1.16 | -10.19 | -0.40 | -3.46 | -1.99 |
| EV to EBITDA | -15.02 | -3.24 | -8.87 | -1.82 | 0.94 | 2.79 | -1.27 | -7.57 | -1.68 | -3.71 | -8.54 | -4.71 | -2.75 | -2.53 | 0.93 | -1.16 | -10.19 | -0.40 | -3.46 | -1.99 |
| Market Capitalization | 555.40M | 336.06M | 486.64M | 232.88M | 119.99M | 90.10M | 190.58M | 398.37M | 173.68M | 221.39M | 410.65M | 244.56M | 152.90M | 123.76M | 62.64M | 99.61M | 269.74M | 108.84M | 150.25M | 165.93M |
| Price to FCFP/FCF | -25.64 | -11.63 | -13.03 | -7.14 | -3.79 | -3.84 | -6.16 | -15.07 | -7.35 | -9.92 | -14.05 | -10.32 | -7.64 | -6.66 | -2.67 | -6.32 | -18.60 | -7.19 | -8.00 | -46.23 |
| EV to FCF | -12.69 | -2.93 | -7.39 | -1.59 | 0.93 | 4.11 | -1.38 | -10.06 | -2.20 | -5.23 | -9.87 | -6.13 | -3.67 | -3.35 | 1.09 | -1.77 | -14.72 | -0.55 | -3.69 | -24.47 |
| EV to CFO | -16.51 | -5.19 | -9.60 | -2.04 | 1.07 | 4.25 | -1.41 | -10.14 | -2.20 | -5.33 | -10.06 | -6.15 | -3.70 | -3.39 | 1.10 | -1.79 | -13.68 | -0.59 | -3.61 | -24.73 |
| Return Ratios | ||||||||||||||||||||
| Return on Sales [ROS]ROS | -8,917.78% | -3,971.89% | ||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -24.70% | -24.17% | -32.59% | -41.70% | -52.48% | -55.01% | -52.79% | -63.49% | -71.55% | -82.40% | -82.77% | -80.69% | -90.45% | -101.45% | -93.15% | -85.54% | -96.86% | -84.45% | -69.12% | -111.10% |
| Return on Assets [ROA]ROA | -23.28% | -22.51% | -30.45% | -38.65% | -48.23% | -48.95% | -47.43% | -55.45% | -61.65% | -68.19% | -70.10% | -69.37% | -77.18% | -85.31% | -80.16% | -74.87% | -83.00% | -71.93% | -58.87% | -90.21% |